List of works - Alessandro Furlan

'Click' synthesis of a triazole-based inhibitor of Met functions in cancer cells.

scientific article

Caspases shutdown nonsense-mediated mRNA decay during apoptosis

scientific article

Combined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signatures

scientific article

Control of cell death/survival balance by the MET dependence receptor

scientific article published on 24 February 2020

Ets-1 controls breast cancer cell balance between invasion and growth.

scientific article published on 5 May 2014

Ets-1 drives breast cancer cell angiogenic potential and interactions between breast cancer and endothelial cells

scientific article published on 24 October 2018

Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment

scientific article published on June 2008

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

scientific article published on May 2017

FRET Image Correlation Spectroscopy Reveals RNAPII-Independent P-TEFb Recruitment on Chromatin

scientific article published in February 2018

How does met regulate the survival/apoptosis balance?

scientific article

Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling ⬇️

scientific article published on November 4, 2011

Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type

scientific article published on 19 February 2020

Mathematical models converge on PGC1α as the key metabolic integrator of SIRT1 and AMPK regulation of the circadian clock

scientific article published on 25 June 2019

Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver.

scientific article published on 10 August 2012

Necrosis- and apoptosis-related Met cleavages have divergent functional consequences

scientific article

ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.

scientific article published on 31 August 2005

Thirty years of research on met receptor to move a biomarker from bench to bedside

scientific article

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer]

scientific article published on 31 August 2018

[P-TEFb and Brd4: actors of the transcription pause release as therapeutical targets]

scientific article published on 01 August 2018

[Thirty years of Met receptor research: from the discovery of an oncogene to the development of targeted therapies].

scientific article published on 14 October 2014

List of works by Alessandro Furlan

'Click' synthesis of a triazole-based inhibitor of Met functions in cancer cells.

Caspases shutdown nonsense-mediated mRNA decay during apoptosis

Combined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signatures

Control of cell death/survival balance by the MET dependence receptor

Ets-1 controls breast cancer cell balance between invasion and growth.

Ets-1 drives breast cancer cell angiogenic potential and interactions between breast cancer and endothelial cells

Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

FRET Image Correlation Spectroscopy Reveals RNAPII-Independent P-TEFb Recruitment on Chromatin

How does met regulate the survival/apoptosis balance?

Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling ⬇️

Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type

Mathematical models converge on PGC1α as the key metabolic integrator of SIRT1 and AMPK regulation of the circadian clock

Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver.

Necrosis- and apoptosis-related Met cleavages have divergent functional consequences

ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.

Thirty years of research on met receptor to move a biomarker from bench to bedside

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer]

[P-TEFb and Brd4: actors of the transcription pause release as therapeutical targets]

[Thirty years of Met receptor research: from the discovery of an oncogene to the development of targeted therapies].